Skip to main content
Clinical Trials/CTRI/2015/05/005830
CTRI/2015/05/005830
Recruiting
Phase 4

Safety and efficacy profile of oral cyclosporine versus oral methotrexate versus oral acitretin in palmoplantar psoriasis and psoriasis vulgaris â?? A hospital based prospective investigator blind randomized controlled comparative study.

Krishna Institute of Medical Sciences Deemed University0 sites120 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: null- Palmoplantar psoriasis and psoriasis vulgaris
Sponsor
Krishna Institute of Medical Sciences Deemed University
Enrollment
120
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Krishna Institute of Medical Sciences Deemed University

Eligibility Criteria

Inclusion Criteria

  • A.Have given written consent before any treatment commenced.
  • B.Be diagnosed to be suffering exclusively from Palmo\-plantar psoriasis either by clinical examination or histopathology if required will be included in palmoplantar psoriasis group.
  • C.Be diagnosed to be suffering from psoriasis vulgaris having more than 20% body surface area will be included in psoriasis vulgaris group.
  • D.Have completed 18 years of age.
  • E.Have to stop any other modality of treatment, two months prior to the inclusion in study.
  • F.Be able and willing, in the view of investigator, to comply all study procedure.

Exclusion Criteria

  • A.Patient with hypersensitivity to drug or patient intolerant to the study medication.
  • B.Pregnant and lactating patient.
  • C.Patient with Unrealistic expectations.
  • D.Not willing for regular follow up.
  • E.Patient with clinically significant cardiovascular, haematological, pancreatic, metabolic neurological or any other laboratory anomaly, which in the judgement of investigator, would interfere in participation in study or proper evaluation.
  • F.Patient on any other systemic drugs therapy which in the judgement of investigator may interfere with interpretation of results.
  • G.Patient having history of tuberculosis or chest X\-ray showing evidence of any infective pathology.

Outcomes

Primary Outcomes

Not specified

Similar Trials